
CytoSorbents (CTSO) Stock Forecast & Price Target
CytoSorbents (CTSO) Analyst Ratings
Bulls say
CytoSorbents Corp has demonstrated a 10% year-over-year increase in product revenues, achieving $9.5 million with gross margins exceeding 70%, indicating improved operational efficiency. The company is experiencing notable revenue growth through its distributor network, particularly outside Germany, where global distribution partner sales rose by 14.4% year-over-year. Additionally, management's strategic focus on advancing innovations like DrugSorb-ATR and the anticipation of returning Germany to growth by 2026 bolster the company's positive outlook.
Bears say
CytoSorbents Corp is experiencing a decline in revenue growth, particularly in Germany, which is its most significant market. Revenue expectations for 2025 and 2026 have been revised downward to $38.2 million and $40.8 million, respectively, reflecting a decrease from previous forecasts. This continuous underperformance in Germany has led to a generally negative outlook for the company's financial performance, further supported by an adjustment in the projected price target.
This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.
CytoSorbents (CTSO) Analyst Forecast & Price Prediction
Start investing in CytoSorbents (CTSO)
Order type
Buy in
Order amount
Est. shares
0 shares